Blog · Evidence, in plain language

Your patient has seen the headset that treats depression at home.

A patient with depression may arrive asking about a headset used at home, and this time the question has a regulator decision behind it: a full FDA approval in December 2025, granted on one remote trial, with the agency doubts printed in its own document and a specialist critique published months later. This post sets out what was approved, what the trial measured, and which parts of the conversation sit in your room and which sit with the prescriber.

By Karel Winner, DNP, PMHNP-BC · Published November 17, 2026

This post is professional education, not clinical guidance for an individual patient. It summarizes a regulator decision, a published trial, and a published critique. Treatment decisions belong to the patient and the clinician treating them.

What the regulator decided, and what it doubted

On December 8, 2025, the Food and Drug Administration granted premarket approval P230024 to the Flow FL-100, made by Flow Neuroscience AB, for the treatment of moderate to severe major depressive disorder in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication. The device delivers transcranial direct current stimulation, a low-intensity direct current through scalp electrodes, and an editorial in Brain Stimulation identifies the decision as the first FDA premarket approval for a home-use non-invasive brain stimulation device specifically indicated for depression treatment. The approval rests mainly on the Empower trial, published in Nature Medicine: a fully remote, multisite, double-blind randomized study of 174 adults in a depressive episode of at least moderate severity, treated at home for 10 weeks. Hamilton Depression Rating Scale scores improved by 9.41 points on active stimulation and 7.14 points on a sham device, a difference of about 2.3 points (P = 0.012), with remission on that scale in 44.9 percent of the active group and 21.8 percent of the sham group.

The limit is stated by the regulator itself. The FDA summary says there is a moderate level of uncertainty of benefit, naming unblinding, the lack of a prespecified clinically significant change in Hamilton scores, and conflicting results from the literature. At week 10, 77.6 percent of the active group correctly guessed their treatment, against 40.7 percent correct guesses on sham, and the agency adjusted estimate of the advantage fell to about 2.0 to 2.12 points. In 2026, a commentary in The Lancet Psychiatry argued that the approval is not yet scientifically justified, that the efficacy evidence is not convincing, and that risks from misuse and unsupervised use have not been addressed. A therapist does not need to adjudicate that dispute. A therapist does need to know it exists, because a patient quoting an approval as settled science is quoting only half of the record.

What belongs in the therapy room

Start with who is asking. The approved wording excludes patients considered resistant to medication, yet those are often the patients most drawn to a non-drug option after years of partial results. Naming that mismatch early, kindly and without closing the topic, protects the patient from building a plan around a group they may not be in. The hope underneath the question is also session material: a wish to do something active each day, frustration with side effects, or a feeling that the current plan has stalled. Each of those points to different work, and only one of them points to a device. The trial sham result gives you an honest observation to offer either way. People using an inactive headset improved substantially over 10 weeks of scheduled sessions, weekly symptom self-reports, and remote monitoring. Structure and measurement helped, in a study designed to subtract them. That is an argument for the tracking and routine your room already builds, whichever treatment decision follows.

Observation remains yours if a patient does use the device. The FDA lists the study adverse effects in plain terms: skin irritation, redness, dry skin, stinging, tingling, numbness or burning during sessions, skin burn in some cases, headache, tinnitus, sleepiness, trouble concentrating during stimulation, and acute mood change or worsening depression. Dated, concrete notes about mood, sleep, and daily functioning across a 10-week course are the notes that let a prescriber judge whether the course is helping. A worsening of mood is not routine observation material. It calls for prompt contact with the treating clinician and the crisis standard below, on the day it is reported, not at the next session.

What belongs to the prescriber

Eligibility is a prescriber judgment, because the indication turns on clinical findings a session cannot settle: whether the episode is moderate to severe major depressive disorder, whether the illness counts as resistant to medication, and whether the presentation is in fact unipolar depression rather than bipolar depression or another condition the approval does not cover. The FDA description also places the device inside monitored care: a clinician platform through which a clinician can follow use and set stimulation parameters, staff supervision of the first use in the trial, and a weekly self-report symptom questionnaire built into the app. The stated limits on use belong to that clinical review as well: no use over open wounds, broken or damaged skin at the electrode site, and no use where there is metallic skull reconstruction at that site. Whether this device should be added to, or substituted within, an existing plan is likewise a prescribing decision, and the trial offers no comparison with an antidepressant, with psychotherapy, or with clinic-based stimulation to settle it. Your contribution to that decision is the longitudinal record only you hold: severity over time, functioning, adherence patterns, and what previous changes actually did.

Sources

U.S. Food and Drug Administration, Summary of Safety and Effectiveness Data, Premarket Approval P230024, Flow FL-100, notice of approval December 8, 2025: the approved indication, the device description, the Empower study results, the blinding analysis, the adverse effects, and the FDA statement of moderate uncertainty of benefit. FDA Summary of Safety and Effectiveness Data.

Woodham and colleagues, Nature Medicine (2025), volume 31, pages 87 to 95: a fully remote, multisite, double-blind, placebo-controlled randomized trial of 10-week home-based transcranial direct current stimulation in major depressive disorder, 174 participants, ClinicalTrials.gov NCT05202119. PubMed record.

Bikson, Brunoni, and George, Brain Stimulation (2026), volume 19, article 103021: the approval is the first FDA premarket approval for a home-use non-invasive brain stimulation device specifically indicated for depression treatment. PubMed record.

Commentary in The Lancet Psychiatry (2026): US FDA premarket approval of tDCS depression treatment is not yet scientifically justified. The authors argue the efficacy evidence is not convincing and that risks from misuse and unsupervised use have not been addressed. The Lancet Psychiatry.

If a patient is having thoughts of harming themselves, the crisis standard applies: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service.